StockNow
Log in
U.S. MarketsIMPORTANT

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

StockNow breaking-news AI analysis

Eli Lilly significantly beat Q2 2026 expectations and raised guidance, driven by dominant GLP-1 drug demand and aggressive manufacturing expansions to secure its lead in the obesity market.

News detail

Zepbound revenue 4.93bln (exp. 4.64bln). Mounjaro revenue 9.943bln. Outlook FY revenue 85-87bln (exp. 85.3bln, prev. 82.0-85.0bln). FY adj. EPS 35.50-36.50 (exp. 35.04).

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Pakistani sources say Pakistan PM Sharif and Army Chief Munir will visit Saudi Arabia tomorrow, Al Hadath reports

U.S. Economy

US ADP Employment Change (Jul) 44K vs. Exp. 70K (Prev. 98K)